HLTRF Stock Chart & Stats
$2.98
-$0.02(-0.67%)
At close: 4:00 PM EDT
$2.98
-$0.02(-0.67%)
Day’s Range― - ―
52-Week Range$2.65 - $4.19
Previous CloseN/A
Volume100.00
Average Volume (3M)52.00
Market Cap
$81.49M
Enterprise Value$177.89
Total Cash (Recent Filing)$13.71M
Total Debt (Recent Filing)$41.84M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Nov 05, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding30,935,060
10 Day Avg. Volume50
30 Day Avg. Volume52
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)1.80
Price to Sales (P/S)1.96
P/FCF Ratio7.00
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$5.94Price Target Upside99.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.17
Revenue Forecast (FY)$41.99M
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationConsistently positive operating and free cash flow gives HLS internal funding capacity for product launches, debt reduction and ongoing operations, reducing dependence on external financing despite reported accounting losses.
Cardiovascular Portfolio GrowthStrong Vascepa growth and early Nilemdo adoption are expanding HLS’s cardiovascular franchise. Broadening prescriber reach and payer coverage can support recurring revenue and improve portfolio margins as launch investments mature.
Deleveraging And Lower Interest BurdenRapid debt reduction and lower interest expense improve financial flexibility and allow more operating cash to support commercialization. A stronger balance sheet also reduces refinancing risk as HLS invests in cardiovascular growth.
Bears Say
Persistent Accounting LossesNegative EBIT, net income and shareholder returns show that cash generation has not yet translated into sustainable bottom-line profitability. Continued losses could limit capital flexibility and weaken the quality of future growth.
Reliance On Pressured Legacy ProductsDeclining and potentially flat U.S. Clozaril sales create a durable offset to cardiovascular expansion. Dependence on established products with weaker demand increases execution risk while newer products scale.
Launch Costs And Margin PressureCommercializing Nilemdo is increasing operating expenses and temporarily reducing EBITDA. Although management expects improvement in H2, sustained investment may delay margin expansion if sales growth or reimbursement uptake develops more slowly.
HLS Therapeutics Inc News
HLTRF FAQ
What was HLS Therapeutics Inc’s price range in the past 12 months?
HLS Therapeutics Inc lowest stock price was $2.65 and its highest was $4.19 in the past 12 months.
What is HLS Therapeutics Inc’s market cap?
HLS Therapeutics Inc’s market cap is $81.49M.
When is HLS Therapeutics Inc’s upcoming earnings report date?
HLS Therapeutics Inc’s upcoming earnings report date is Nov 05, 2026 which is in 69 days.
How were HLS Therapeutics Inc’s earnings last quarter?
HLS Therapeutics Inc released its earnings results on Aug 12, 2026. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.08 by $0.05.
Is HLS Therapeutics Inc overvalued?
According to Wall Street analysts HLS Therapeutics Inc’s price is currently Undervalued.
Does HLS Therapeutics Inc pay dividends?
HLS Therapeutics Inc pays a Quarterly dividend of $0.037 which represents an annual dividend yield of N/A. See more information on HLS Therapeutics Inc dividends here
What is HLS Therapeutics Inc’s EPS estimate?
HLS Therapeutics Inc’s EPS estimate is -0.07.
How many shares outstanding does HLS Therapeutics Inc have?
HLS Therapeutics Inc has 30,935,060 shares outstanding.
What happened to HLS Therapeutics Inc’s price movement after its last earnings report?
HLS Therapeutics Inc reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.08. Following the earnings report the stock price went up 2.182%.
Which hedge fund is a major shareholder of HLS Therapeutics Inc?
Currently, no hedge funds are holding shares in HLTRF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HLS Therapeutics Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.94 (99.35% Upside)
$5.94 (99.35% Upside)
Blogger Sentiment
Bullish
HLTRF Sentiment 100%
Sector Average 60%
Sector Average 60%
Insider Transactions
Bought Shares
Worth $25.5K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
36.71%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-10.34%
Trailing 12-Months
Company Description
HLS Therapeutics Inc
HLS Therapeutics Inc. operates as a specialized pharmaceutical firm, concentrating on the acquisition and commercialization of medicinal products, primarily within the niche central nervous system (CNS) and cardiovascular (CV) sectors. Its reach extends across Canada, the United States, and international markets. The company's core product lineup includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsule formulation; and PERSERIS, an injectable risperidone product for treating schizophrenia. Additionally, HLS offers MyCare psychiatry laboratory assays and MyCare Insite tests for point-of-care therapeutic drug-level monitoring. Furthermore, the company possesses U.S. marketing privileges for Absorica, a commercial-stage dermatology solution, and Canadian rights for Trinomia, a cardiovascular therapeutic. It also manages a portfolio of royalty interests from four distinct healthcare products. Founded in 2018, HLS Therapeutics Inc. is based in Etobicoke, Canada.
HLTRF Stock 12 Month Forecast
Average Price Target
$5.94
▲(99.35% Upside)
Knight Therapeutics
―
Cipher Pharmaceuticals
―
Aequus Pharmaceuticals
―
Medexus Pharmaceuticals Inc
―
Biosyent
―
Ownership Overview
0.09% Insiders
0.01% Mutual Funds
1.61% Other Institutional Investors
98.26% Public Companies and
Individual Investors